Ponoi II Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Ponoi II Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17M	Hold	1,298,908	–	–	44.41%	1
2022 Q2	$16.7M	Hold	1,298,908	–	–	45.25%	1
2022 Q1	$19.8M	Hold	1,298,908	–	–	43.96%	1
2021 Q4	$23M	Hold	1,298,908	–	–	41.78%	1
2021 Q3	$27.3M	Hold	1,298,908	–	–	40.46%	1
2021 Q2	$25.6M	Hold	1,298,908	–	–	20.76%	2
2021 Q1	$37.8M	Hold	1,298,908	–	–	28.92%	1
2020 Q4	$39.4M	Buy	+1,298,908	New	+$28.4M	28.68%	2

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ponoi II Management's NGM Position: Q3 2022 in Review

Ponoi II Management held its NGM Biopharmaceuticals, Inc. Common Stock (NGM) position steady in Q3 2022 at 1,298,908 shares worth $17M. The position accounts for 44.41% of the portfolio, ranked #1.

Ponoi II Management first reported a position in NGM in Q4 2020 and has held it in 8 quarters since. The position peaked at $39.4M in Q4 2020. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

Ponoi II Management held 1,298,908 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $17M as of Q3 2022.
Ponoi II Management left its NGM Biopharmaceuticals, Inc. Common Stock share count unchanged in Q3 2022.
NGM Biopharmaceuticals, Inc. Common Stock made up 44.41% of Ponoi II Management's portfolio in Q3 2022, its #1 holding.
Ponoi II Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and has held it in 8 quarters since.
Ponoi II Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $39.4M in Q4 2020.
128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Ponoi II Management's 13F filing for Q3 2022, filed 14 Nov 2022.